- Home
- LPG vs REPL Comparison
LPG vs REPL Comparison
Compare LPG & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- REPL
- Stock Information
- Founded
- LPG 2013
- REPL 2015
- Country
- LPG United States
- REPL United States
- Employees
- LPG N/A
- REPL N/A
- Industry
- LPG Marine Transportation
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- REPL Health Care
- Exchange
- LPG Nasdaq
- REPL Nasdaq
- Market Cap
- LPG 913.3M
- REPL 757.8M
- IPO Year
- LPG 2014
- REPL 2018
- Fundamental
- Price
- LPG $29.01
- REPL $3.14
- Analyst Decision
- LPG Strong Buy
- REPL Buy
- Analyst Count
- LPG 1
- REPL 10
- Target Price
- LPG $35.00
- REPL $8.25
- AVG Volume (30 Days)
- LPG 577.3K
- REPL 9.1M
- Earning Date
- LPG 08-04-2025
- REPL 08-07-2025
- Dividend Yield
- LPG 10.84%
- REPL N/A
- EPS Growth
- LPG N/A
- REPL N/A
- EPS
- LPG 2.14
- REPL N/A
- Revenue
- LPG $349,670,662.00
- REPL N/A
- Revenue This Year
- LPG $12.19
- REPL N/A
- Revenue Next Year
- LPG N/A
- REPL N/A
- P/E Ratio
- LPG $13.80
- REPL N/A
- Revenue Growth
- LPG N/A
- REPL N/A
- 52 Week Low
- LPG $16.66
- REPL $2.68
- 52 Week High
- LPG $42.38
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- LPG 66.15
- REPL 24.39
- Support Level
- LPG $27.83
- REPL $2.68
- Resistance Level
- LPG $29.80
- REPL $3.85
- Average True Range (ATR)
- LPG 0.83
- REPL 0.79
- MACD
- LPG 0.05
- REPL -1.03
- Stochastic Oscillator
- LPG 80.59
- REPL 3.50
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.